Reviewing Lombard Medical (OTCMKTS:EVARF) and Lyra Therapeutics (NASDAQ:LYRA)

Lombard Medical (OTCMKTS:EVARF) and Lyra Therapeutics (NASDAQ:LYRA) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, analyst recommendations, valuation, institutional ownership, dividends, profitability and risk.

Analyst Recommendations

This is a breakdown of recent ratings for Lombard Medical and Lyra Therapeutics, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lombard Medical	0	0	0	0	0.00
Lyra Therapeutics	1	4	1	0	2.00

Lyra Therapeutics has a consensus target price of $4.50, indicating a potential upside of 2,087.65%. Given Lyra Therapeutics’ stronger consensus rating and higher possible upside, analysts plainly believe Lyra Therapeutics is more favorable than Lombard Medical.

Earnings and Valuation

This table compares Lombard Medical and Lyra Therapeutics”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lombard Medical	N/A	N/A	N/A	N/A	N/A
Lyra Therapeutics	$1.56 million	8.63	-$62.68 million	($1.49)	-0.14

Lombard Medical has higher earnings, but lower revenue than Lyra Therapeutics.

Insider & Institutional Ownership

95.6% of Lyra Therapeutics shares are held by institutional investors. 4.7% of Lyra Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Profitability

This table compares Lombard Medical and Lyra Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Lombard Medical	N/A	N/A	N/A
Lyra Therapeutics	-6,635.76%	-125.07%	-59.74%

Summary

Lyra Therapeutics beats Lombard Medical on 6 of the 9 factors compared between the two stocks.

About Lombard Medical

Lombard Medical, Inc., a medical technology company, develops, manufactures, and markets endovascular stent-grafts for the repair of aortic aneurysms in the United States, the United Kingdom, Germany, Japan, and internationally. The company’s principal product is Aorfix, which is an endovascular stent-graft for the treatment of abdominal aortic aneurysms (AAAs) with angulation at the neck of the aneurysm of up to 90 degrees. Its products also include Altura endovascular stent graft system for the treatment of standard AAA anatomies; Aorflex delivery system for accurate placement of Aorfix in the abdominal aorta; and IntelliFlex LP delivery system that enhances the precision and control of Aorfix deployment and placement. Lombard Medical, Inc. sells its products directly through its direct sales force and distributors to state-or-government-owned hospitals. The company was founded in 2000 and is headquartered in Didcot, the United Kingdom.

About Lyra Therapeutics

Lyra Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. It's XTreo technology platform is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration. The company's product candidates include LYR-210, an anti-inflammatory implantable drug matrix for the treatment of chronic rhinosinusitis (CRS), which is in Phase III clinical trial; and LYR-220 for CRS patients with and without nasal polyps. It has a collaboration agreement with LianBio Inflammatory Limited to develop and commercialize LYR-210 in mainland China, Hong Kong, Taiwan, Macau, South Korea, Singapore, and Thailand. The company was formerly known as 480 Biomedical, Inc. and changed its name to Lyra Therapeutics, Inc. in July 2018. Lyra Therapeutics, Inc. was incorporated in 2005 and is headquartered in Watertown, Massachusetts.